General Partners

Venture Partners




Kenneth S. Abramowitz

Kenneth S. Abramowitz is a co-founder and Managing General Partner of NGN Capital. He joined NGN Capital from The Carlyle Group in New York where he was Managing Director from 2001 to 2003, focused on U.S. buyout opportunities in the healthcare industry. Beginning July 2003, he transitioned to Senior Advisor at Carlyle in order to devote the time necessary to create a dedicated healthcare fund on behalf of Carlyle. Prior to joining Carlyle, Mr. Abramowitz worked as an Analyst at Sanford C. Bernstein & Co. where he covered the medical-supply, hospital-management and HMO industries for 23 years, after which he was an EGS Securities Healthcare Fund Manager. He was voted top hospital supply and/or service analyst on the Institutional Investor Magazine "All-America Research Team" during 14 out of 20 years between 1980-2000 and made “The Team” for both healthcare services and medical supplies for 9 years since 1987. Mr. Abramowitz has published several notable studies on healthcare service companies, major medical mergers, and cardiovascular device innovation, among others. He has also published numerous articles in leading journals. Mr. Abramowitz earned a B.A. from Columbia University in 1972 and an M.B.A. from Harvard Business School in 1976. Mr. Abramowitz currently sits on the Board of Directors of Valtech Cardio Ltd., Small Bone Innovations, Inc. and Akorn, Inc., and serves as a board observer at OptiScan Biomedical Corp., BeneChill, Inc., Cerapedics, Inc., and Spine View, Inc. He previously served as a Director at Sightline Technologies Ltd, acquired by Stryker, Power Medical Interventions, acquired by Covidien, EKOS Corp.,  acquired by BTG and MultiPlan, acquired by BC Partners and Silver Lake, as well as on the boards of MedPointe and ConnectiCare Holdings, Inc.




John R. Costantino

John R. Costantino is a Managing General Partner at NGN Capital with 20 years of private equity experience. He was formerly a Partner of Walden Partners, a merchant/investment banking firm and Walden Capital Partners. Prior to these assignments, Mr. Costantino was a partner in Costantino, Melamede & Greenberg, an investment partnership which specialized in acquiring and managing growth businesses. He was also Senior Executive Vice President & COO and a Director of Conair, a leading personal care company with over $1 billion of revenues. He was also President and a Managing Director of Integrated Resources Acquisition, a leveraged buyout firm. He started his career at Touche Ross, a major accounting firm where he became the firm’s managing tax partner in New York. Mr. Costantino is a trustee of General Electric’s family of mutual funds. He holds a B.S. and J.D. from Fordham University and is also a C.P.A. Mr. Costantino is Chairman of Enzybiotics, Inc. and Senior Advisor to Promosome LLC, two biotechnology start-ups formed prior to NGN Capital. He also serves on the Board of Directors of ACT Biotech, a spin-out from Bayer Pharmaceuticals and Vivaldi Biosciences and as a board observer at Valtech Cardio. He continues to participate and has served on a number of other domestic and international boards.


Peter Johann, Ph.D.

Dr. Peter Johann is a Managing General Partner of NGN Capital. He joined from Boehringer Ingelheim where he was the Division Head of Corporate Development. Dr. Johann has established a worldwide network in the Biotech and Pharmaceutical Industry. His responsibilities at Boehringer Ingelheim included strategic planning, strategic projects, M&A, business development and licensing. He identified and evaluated several licensing, M&A and co-promotion deals. Prior to this Dr. Johann served at F. Hoffmann-La Roche as Global Business Leader where he led global business teams and was responsible for global marketing of oncology products as well as evaluation of pipeline products from internal and external sources. Dr. Johann joined Roche from Boehringer Mannheim where he was Head of Business Development and Marketing Molecular Medicine. Besides marketing activities Dr. Johann was involved in setting up and managing joint venture companies as member of the supervisory board. He was also responsible for licensing activities in this field. Prior to that position he had Marketing, Sales and Business Development responsibilities at Boehringer Mannheim Biochemicals, among others, for collaborations in the field of Biopharmaceuticals. Dr. Johann has additional industry experience in Business Development and Marketing of pharmaceutical products with Kaneka in Japan and with Röhm in Germany in industrial enzymes. Dr. Johann obtained his Ph.D. from the Technical University Munich. He currently serves on the Board of Directors of Horizon Pharma, Inc., Vivaldi Biosciences, Inc., Resverlogix Corporation, Noxxon Pharma AG and Exosome Diagnostics, Inc. He previously served on the Board of Directors of Jerini AG (FWB: J14), acquired by Shire Pharmaceuticals, Micromet (Nasdaq: MITI), which was acquired by Amgen and NaniRx Therapeutics and as an observer on the board of Santhera Pharmaceuticals AG and Cerapedics, Inc.


Top of Page

Ivica Čerina, Ph.D.

Dr. Cerina is a Partner of NGN Capital. Ivica Cerina, Ph.D. joined NGN Capital in 2005 from DyoDelta Biosciences Ltd. where he was VP Venture Financing & Business Development. Prior to that, he gained 6 years of venture capital experience at TVM - a leading German-U.S. venture firm with over €1.2B under management - where he was responsible for deal sourcing, due diligence, deal support and business development. At TVM he worked with the partners on existing portfolio companies and new transactions (e.g. Addex, Jerini, SelectX, Direvo) and established a strong international network with leading venture firms, investment banks, biotech & pharma companies. Prior to TVM, Dr. Cerina worked as a consultant advising start-ups and small and mid-size entities on financing and business strategy. Dr. Cerina studied Biochemistry at the J.W.Goethe University in Frankfurt and performed his doctorate thesis at the Hemostasis Research Unit of the Max-Planck-Institute for Physiological & Clinical Research in Bad Nauheim. Dr. Cerina currently serves on the Board of Directors of PIN Pharma and holds an observer seat on the board of Vivaldi Biosciences and previously held and observer seat on the board of Vivaldi Biosciences.




Noah J. Kroloff

Mr. Kroloff is a Partner of NGN Capital. Noah J. Kroloff has more than 22 years of experience in healthcare, including senior operating roles. Prior to joining NGN Capital, Mr. Kroloff was an executive officer of i-STAT Corporation (Nasdaq: STAT), a medical device company where he served as Vice President for International Sales & Marketing and Corporate Development. He was actively involved in the sale of i-STAT to Abbott Laboratories for approximately $450 million. He also led the creation of a global alliance with Abbott and a $61 million alliance with Hewlett-Packard Medical Products Group, created i-STAT’s international distribution network and led licensing and deal-making activities. Prior to i-STAT, Mr. Kroloff was an Engagement Manager at McKinsey & Co. where he advised leading pharmaceutical and diagnostic companies on R&D management, portfolio strategy, and alliance formation. He has also performed significant work for Merck and Rosetta Genomics. Prior to his work in healthcare, he was a senior analyst at Fannie Mae and an associate at Industrial Economics, Inc. Mr. Kroloff received his BA in general science from Brandeis University and his MBA from the MIT Sloan School   where he co-founded and serves as a judge of the MIT $100K Entrepreneurship Competition.  Mr. Kroloff is a member of the Board of Directors of BeneChill, Inc., Valtech Cardio Ltd., Cerapedics, Inc. and Coagulation Sciences LLC and is a member of McKinsey’s alumni advisory council and the Technion NY Metro board.




Leonard Hirsch

Leonard P. Hirsch, CPA, is the Chief Financial Officer of NGN Capital. Mr. Hirsch comes to NGN Capital with over 15 years of experience in tax, accounting and financial administration. Most recently he was the Chief Financial Officer of Wheatley Partners, a venture capital group with $300 million under management, focused on software and technology related investments. In this role he was responsible for financial and tax reporting, limited partner communications, and fund administration. Prior to this position, he worked with a technology start-up as it grew from about twenty to over 100 employees upon the completion of venture capital financing. Mr. Hirsch’s responsibilities included financial reporting, tax compliance, budgeting, development of accounting policies, and general administrative matters. Mr. Hirsch began his career with PricewaterhouseCoopers, spending seven years in the New York office and specializing in corporate and partnership taxation. His clients ranged from start-ups to multinational corporations in the consumer, media, retail and financial service sectors. Mr. Hirsch received a B.S in business administration from the University of Vermont and a Masters in Accounting and Taxation from Fordham University.


Top of Page



Kenneth J. Gorelick, M.D.

Kenneth Gorelick, M.D. has 20 years of experience in the development of drugs and biologics in the human health care sector. He is currently President and Chief Operating Officer of Enzybiotics, LLC, a privately held biotechnology company and a consultant to the pharmaceutical industry. Dr. Gorelick has expertise with numerous approvals of BLAs, NDAs and MAAs. Prior to these assignments, Dr. Gorelick held the position of Vice President of Global Clinical Research and Development at Dupont Merck Research Laboratories, Inc. a research-driven pharmaceutical company. He was also Vice President of Drug Development at Genelabs, a biotechnology company focused on infectious and autoimmune disease. Dr. Gorelick was Clinical Associate Professor of Medicine at Stanford University until 2000. He holds a B.S. from the State University of New York at Buffalo and a M.D. from Weill Medical College of Cornell University. He is Board Certified in Internal Medicine and Pulmonary Diseases. He is a Fellow of the American College of Chest Physicians.


Leon Y. Recanati

Leon Y. Recanati is currently the Chairman and CEO of GlenRock Israel Ltd., a private investment company whose main field of activity is venture capital investments in startup companies engaged in life sciences, biotechnology, medical devices, and in advanced technologies. Until May 2003, and prior to founding GlenRock, he served as Chairman & CEO of IDB Holding Corporation Ltd., Chairman of Clal Industries and Investments Ltd., and Chairman of Azorim Investment Development and Construction Ltd., in addition to several other positions in a variety of operating companies in Israel. Mr. Recanati initiated in 1998 Clal Biotechnologies Ltd. (CBL). Clal Industries invested $100 million in CBL. Clal Biotechnologies is considered the largest biotechnology investment company operating in Israel. Mr. Recanati has a M.B.A. and B.S. from The Hebrew University of Jerusalem and Honorary Doctorate degrees from the Technion - Israel Institute of Technology and Tel Aviv University. Mr. Recanati is actively heading numerous charitable enterprises in Israel..



Colin B. Bier, PhD

Colin B. Bier, PhD is currently the Managing Director of ABA BioResearch, Inc., a bioregulatory consulting firm. He is also currently the Acting Chief Scientific Officer of Enzybiotics, Inc. and a Senior Advisor to TVM Venture Capital. Dr. Bier has had experience in operating, medical, scientific and strategic advisory roles at a variety of pharma/biopharma companies. At present, he is a member of the Boards of Directors of two public companies, Bellus Health and Advitech, Inc., as well as serving on other private company boards. He is on the Board of Directors of Mt. Sinai Hospital (Montreal) and holds an appointment at The Center for Translational Research in cancer at the Jewish General Hospital (Montreal). Dr. Bier earned a Ph.D. in Experimental Pathology at Colorado State University and was the former Medical Research Council Postdoctoral Fellow and The Dr. Douglas James Fellow in the Department of Pathology at McGill University.


William J. Gedale

William J. Gedale is a Senior Advisor and co-founder of NGN Capital. He has been in the investment business since 1965. Mr. Gedale joined NGN from Mount Everest Advisors, which he founded in 1996. He has served as an investment advisor to individuals and as a full time consultant to Warburg-Pincus Capital Management, the world's largest venture capital firm, between 1999 and 2001. In this capacity, he initiated the $140 million dollar financing of ZymoGenetics. He also helped arrange the $350 million funding by Sandoz (Novartis) of the Scripps Research Institute and the $40 million funding of the Neuroscience Institute of La Jolla, California (of which he is a trustee). Before founding Mount Everest Advisors he was a Managing Director at John W. Bristol & Co. in 1995. Before this, as of 1989, Mr. Gedale was President & Chief Executive Officer of General American Investors, which he had joined in 1969. He is currently Chairman of Promosone and Vice Chairman of Enzybiotics. He has been a director of Gamco (Gabelli Holding), General American Investors, Allied Clinical Laboratories, U.S. Home Health Care, Unilab Corporation, and BioReliance Corporation. William Gedale holds an M.B.A. from New York University, a J.D. from Fordham Law School, and an A.B. from Syracuse University. He currently serves on the Board of Directors of PIN Pharma and previously served on the Board of Directors of KIKA Medical Inc., acquired by Merge Healthcare, and BioArray Solutions, acquired by Immucor.